Ebenbuild has received funding of €2.3 million as part of the accelerator program of the European Innovation Council (EIC). Additionally, the EIC Fund is offering up to €10 million for future equity financing. The funding supports the further development and scaling of the company’s digital twin platform technology.
Central to the strategy is the software Twinhale, which digitally simulates the delivery of medicines via the lungs. According to Ebenbuild, Twinhale is the first scalable simulation tool that enables patient-specific, physiologically accurate predictions of drug deposition in the lungs. The target audience is pharmaceutical and medical device companies that can reduce costs, failure rates, and time to market with this technology.
Pilot studies completed successfully
Ebenbuild has already deployed Twinhale in pilot studies with PARI Pharma and Pieris Pharmaceuticals. In a validation study, Twinhale predicted local drug deposition with high accuracy. The software outperformed existing models and enabled design decisions that would not have been possible with in vivo or in vitro tests.
“Our vision is to become the leading health information platform for respiratory diseases. Twinhale is just the beginning. The same core platform will also support future regulated products for optimizing mechanical ventilation and managing chronic respiratory diseases,”
says Dr. Kei Müller, CEO and co-founder of Ebenbuild.
Market entry into CDSS and personalized medicine planned
Ebenbuild is planning long-term entry into the markets for clinical decision support systems (CDSS) and personalized medicine. According to the company, the market potential for these areas will exceed €300 billion by 2030. Today, the startup is already active in the global in silico studies market, which is worth over €5 billion. Ebenbuild is supported by HTGF, Bayern Kapital, and several angel investors.
“With Twinhale, we not only reduce failure rates in respiratory drug development, but also generate unique datasets that advance regulatory approvals and could enable companion diagnostic strategies in the future,”
said Dr. Maximilian Grill, head of in silico studies at Ebenbuild.
Ebenbuild’s product roadmap ranges from preclinical simulations to software solutions for optimizing ventilation in patients with lung complications. The current EIC funding is considered non-dilutive capital and validation from one of Europe’s most demanding funding programs for tech startups.
